Pharmacokinetic Prediction of Levofloxacin Accumulation in Tissue and Its Association to Tendinopathy

Loan Pham, John M. Christensen, Rosita Rodriguez-Proteau

Camargo Pharmaceuticals, Cincinnati, USA.
Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, USA.

DOI: 10.4236/pp.2013.41018                

Abstract

Objectives: We investigated pharmacokinetic tissue distributions of Levofloxacin to explain adverse tendon incidents. Methods: The pharmacokinetic profiles of single and multiple dosing of 500 mg Levofloxacin following oral and IV infusion administration were simulated. Monte Carlo simulation was used to simulate the drug concentration profiles in plasma and tissue after seven dosing regimens while varying the drug’s elimination and distribution rates to analyze the effects of changing those rates on Levofloxacin accumulation in tissue. Results: Simulated data following oral and IV administration reflect well the reported data (mean simulated plasma Cmax = 6.59 μg/mL and 5.19 μg/mL for IV and oral versus 6.4 μg/mL and 5.2 μg/mL for observed clinical IV and oral route, respectively). Simulations of seven repetitive doses are also in agreement with reported values. Low elimination rates affect the drug concentration in plasma and tissue significantly with the concentration in plasma rising to 35 μg/mL at day 7. Normal elimination rates together with escalation of distribution rates from plasma to tissue increase tissue concentration after 7 doses to 9.5 μg/mL, a value is more than twice that of normal. Conclusions: Simulation can be used to evaluate drug concentration in different tissues. The unexpectedly high concentrations in some cases may explain the reason for tendinopathy in clinical settings.

Keywords

Monte Carlo Simulation; Tendon Incidents; Levofloxacin; Pharmacokinetic

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	A. Durey, et al., “Levofloxacin-Induced Achilles Tendinitis in a Young Adult in the Absence of Predisposing Conditions,” Yonsei Medical Journal, Vol. 51, No. 3, 2010, pp. 454-456. doi:10.3349/ymj.2010.51.3.454
[2]	J. B. Kahn, “Latest Industry Information on the Safety Profile of Levofloxacin in the US,” Chemotherapy, Vol. 47, Suppl. 3, 2001, pp. 32-37. doi:10.1159/000057842
[3]	A. S. Mathis, et al., “Levoflox-acin-Associated Achilles Tendon Rupture,” Annals of Pharmacotherapy, Vol. 37, No. 7-8, 2003, pp. 1014-1017. doi:10.1345/aph.1C505
[4]	A. Melhus, et al., “Levoflox-acin-Associated Achilles Tendon Rupture and Tendinopathy,” Scandinavian Journal of Infectious Diseases, Vol. 35, No. 10, 2003, pp. 768-770. doi:10.1080/00365540310015863
[5]	J. R. Lewis, J. G. Gums and D. L. Dickensheets, “Levoflox-acin-Induced Bilateral Achilles Tendonitis,” Annals of Pharmacotherapy, Vol. 33, No. 7-8, 1999, pp. 792-795. doi:10.1345/aph.18298
[6]	F. Fleisch, K. Hartmann and M. Kuhn, “Fluoroquinolone-Induced Tendinopathy: Also Occurring with Levofloxacin,” Infection, Vol. 28, No. 4, 2000, pp. 256-257. doi:10.1007/s150100070050
[7]	L. J. Haddow, et al., “Spontaneous Achilles Tendon Rupture in Patients Treated with Levofloxacin,” Journal of Antimicrobial Chemotherapy, Vol. 51, No. 3, 2003, pp. 747-748. doi:10.1093/jac/dkg081
[8]	C. Parmar and K. P. Meda, “Achilles Tendon Rupture Associated with Combination Therapy of Levofloxacin and Steroid in Four Patients and a Review of the Literature,” Foot & Ankle International, Vol. 28, No. 12, 2007, pp. 1287-1289. doi:10.3113/FAI.2007.1287
[9]	H. von Baum, et al., “Tissue and Serum Concentrations of Levofloxacin in Orthopaedic Patients,” International Journal of Antimicrobial Agents, Vol. 18, No. 4, 2001, pp. 335-340. doi:10.1016/S0924-8579(01)00423-X
[10]	M. A. Zeitlinger, et al., “A Pilot Study Testing Whether Concentrations of Levof-loxacin in Interstitial Space Fluid of Soft Tissues May Serve as a Surrogate for Predicting Its Pharmacokinetics in Lung,” International Journal of Antimicrobial Agents, Vol. 29, No. 1, 2007, pp. 44-50. doi:10.1016/j.ijantimicag.2006.08.045
[11]	K. De Angelis, et al., “Blood Flow Measurements in Rats Using Four Color Mi-crospheres during Blockade of Different Vasopressor Systems,” Brazilian Journal of Medical and Biological Research, Vol. 38, No. 1, 2005, pp. 119-125. doi:10.1590/S0100-879X2005000100018
[12]	D. M. Boothe, et al., “Tissue Concentrations of Enrofloxacin and Ciprofloxacin in Anesthetized Dogs Following Single Intravenous Administration,” Veterinary Therapeutics, Vol. 2, No. 2, 2001, pp. 120-128.
[13]	M. N. Doral, et al., “Functional Anatomy of the Achilles Tendon,” Knee Surgery, Sports Traumatology, Arthroscopy, Vol. 18, No. 5, 2010, pp. 638-643. doi:10.1007/s00167-010-1083-7
[14]	J. M. Casparian, et al., “Quinolones and Tendon Ruptures,” Southern Medical Journal, Vol. 93, No. 5, 2000, pp. 488-491.
[15]	M. M. Hall, J. T. Finnoff and J. Smith, “Musculoskeletal Complications of Fluoro-quinolones: Guidelines and Precautions for Usage in the Athletic Population,” PM & R, Vol. 3, No. 2, 2011, pp. 132-142. doi:10.1016/j.pmrj.2010.10.003
[16]	Y. Kashida and M. Kato, “Characterization of Fluoroquinolone-Induced Achilles Tendon Toxicity in Rats: Comparison of Toxicities of 10 Fluoroquinolones and Effects of Anti-Inflammatory Compounds,” Antimi-crobial Agents and Chemotherapy, Vol. 41, No. 11, 1997, pp. 2389-2393.
[17]	P. D. van der Linden, et al., “Increased Risk of Achilles Tendon Rupture with Quinolone Antibacterial Use, Especially in Elderly Patients Taking Oral Corticosteroids,” Archives of Internal Medicine, Vol. 163, No. 15, 2003, pp. 1801-1807. doi:10.1001/archinte.163.15.1801
[18]	Levaquin NDA 020634 Approval Package Study #K09-077 and LOF-BIV-MULT-001, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020634_levaquin_toc.cfm
[19]	R. Bellmann, et al., “Tissue Pharma-cokinetics of Levofloxacin in Human Soft Tissue Infections,” British Journal of Clinical Pharmacology, Vol. 57, No. 5, 2004, pp. 563-568. doi:10.1111/j.1365-2125.2004.02059.x
[20]	T. Rimmele, et al., “Diffusion of Levofloxacin into Bone and Synovial Tissues,” Journal of Antimicrobial Chemotherapy, Vol. 53, No. 3, 2004, pp. 533-535. doi:10.1093/jac/dkh110
[21]	C. B. Landersdorfer, et al., “Penetration of Antibacterials Into Bone: Pharmacokinetic, Phar-macodynamic and Bioanalytical Considerations,” Clinical Pharmacokinetics, Vol. 48, No. 2, 2009, pp. 89-124. doi:10.2165/00003088-200948020-00002
[22]	F. Pea, “Penetration of Antibacterials Into Bone: What Do We Really Need to Know for Optimal Prophylaxis and Treatment of Bone and Joint Infections?” Clinical Pharmacokinetics, Vol. 48, No. 2, 2009, pp. 125-127. doi:10.2165/00003088-200948020-00003
[23]	S. C. Chien, et al., “Pharmacokinetic Profile of Levofloxacin Following Once-Daily 500-Milligram Oral or Intravenous Doses,” Anti-microbial Agents and Chemotherapy, Vol. 41, No. 10, 1997, pp. 2256-2260.
[24]	J. E. Mazuski, et al., “The Surgical Infection Society Guidelines on Antimicrobial Therapy for Intra-Abdominal Infections: Evidence for the Recommendations,” Surgical Infections, Vol. 3, No. 3, 2002, pp. 175-233. doi:10.1089/109629602761624180
[25]	New Drug Application 20-634, 2012. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist
[26]	Levaquin NDA 020634 Label, 2012.
[27]	F. Pouzaud, et al., “In Vitro Discrimination of Fluoroquinolones Toxicity on Tendon Cells: Involvement of Oxidative Stress,” Journal of Pharmacology and Experimental Therapeutics, Vol. 308, No. 1, 2004, pp. 94-402.
[28]	K. Yabe, et al., “A Non-Arthropathic Dose and Its Disposition Following Repeated Oral Administration of Oflox-acin, a New Quinolone Antimicrobial Agent, to Juvenile Dogs,” Journal of Veterinary Medical Science, Vol. 63, No. 8, 2001, pp. 867-872. doi:10.1292/jvms.63.867
[29]	A. Meissner, K. Borner and P. Koeppe, “Concentrations of Ofloxacin in Human Bone and in Cartilage,” Journal of Antimicrobial Chemotherapy, Vol. 26, Suppl. D, 1990, pp. 69-74.
[30]	P. D. van der Linden, et al., “Tendon Disorders Attributed to Fluoroquinolones: A Study on 42 Spontaneous Reports in the Period 1988 to 1998,” Arthritis & Rheumatism, Vol. 45, No. 3, 2001, pp. 235-239. doi:10.1002/1529-0131(200106)45:3<235::AID-ART254>3.0.CO;2-7
[31]	J. M. Michot, et al., “Influence of Efflux Transporters on the Accumulation and Efflux of Four Quinolones (Ciprofloxacin, Levofloxacin, Garenoxacin, and Moxifloxacin) in J774 Macrophages,” Antimicrobial Agents and Chemotherapy, Vol. 49, No. 6, 2005, pp. 2429-2437. doi:10.1128/AAC.49.6.2429-2437.2005
[32]	J. T. Jagose, et al., “Achilles Tendon Rupture Due to Ciprofloxacin,” New Zealand Medical Journal, Vol. 109, No. 1035, 1996, pp. 471-472.
[33]	Y. Khaliq and G. G. Zhanel, “Fluoroquino-lone-Associated Tendinopathy: A Critical Review of the Literature,” Clinical Infectious Diseases, Vol. 36, No. 11, 2003, pp. 1404-1410. doi:10.1086/375078
[34]	M. H. Gotfried, L. H. Danziger and K. A. Rodvold, “Steady-State Plasma and Intra-pulmonary Concentrations of Levofloxacin and Ciprofloxacin in Healthy Adult Subjects,” Chest, Vol. 119, No. 4, 2001, pp. 1114-1122. doi:10.1378/chest.119.4.1114
[35]	S. Swoboda, et al., “Tissue and Serum Concentrations of Levofloxacin 500 mg Administered Intravenously or Orally for Antibiotic Prophylaxis in Biliary Surgery,” Journal of Antimicrobial Chemotherapy, Vol. 51, No. 2, 2003, pp. 459-462. doi:10.1093/jac/dgk056
[36]	A. Boeckh, et al., “Time Course of Enrofloxacin and Its Active Metabolite in Peripheral Leukocytes of Dogs,” Veterinary Therapeutics, Vol. 2, No. 4, 2001, pp. 334-344.
[37]	M. B. Carlier, et al., “Cellular Uptake, Localization and Activity of Fluoroquinolones in Uninfected and Infected Macrophages,” Journal of Antimicrobial Chemotherapy, Vol. 26, Suppl. B, 1990, pp. 7-39.
[38]	P. Schuler, et al., “Penetration of Sparfloxacin and Ciprofloxacin into Alveolar Macrophages, Epithelial Lining Fluid, and Polymorphonuclear Leucocytes,” European Respiratory Journal, Vol. 10, No. 5, 1997, pp. 1130-1136. doi:10.1183/09031936.97.10051130
[39]	K. Taira, H. Koga and S. Kohno, “Accumulation of a Newly Developed Fluoro-quinolone, OPC-17116, by Human Polymorphonuclear Leuko-cytes,” Antimicrobial Agents and Chemotherapy, Vol. 37, No. 9, 1993, pp. 1877-1881. doi:10.1128/AAC.37.9.1877
[40]	P. M. Tulkens, “Accumulation and Subcellular Distribution of Antibiotics in Macrophages in Relation to Activity against Intracellular Bacteria,” Ciprofloxacinn in Pulmonology, San Francisco, 1990.
[41]	R. P. Smith, et al., “Levofloxacin Penetrates Human Monocytes and Enhances Intracellular Killing of Staphylococcus aureus and Pseudomonas aeruginosa,” Journal of Antimicrobial Chemotherapy, Vol. 45, No. 4, 2000, pp. 483-488. doi:10.1093/jac/45.4.483
[42]	M. Egerbacher, B. Wolfesberger and C. Gabler, “In Vitro Evidence for Effects of Magnesium Supplementation on Quinolone-Treated Horse and Dog Chondrocytes,” Veterinary Pathology, Vol. 38, No. 2, 2001, pp. 143-148. doi:10.1354/vp.38-2-143
[43]	D. Vazifeh, A. Bryskier and M. T. Labro, “Mechanism underlying levofloxacin Uptake By human polymorphonuclear neutrophils,” Antimicrobial Agents and Chemotherapy, Vol. 43, No. 2, 1999, pp. 246-252.
[44]	M. Kato, et al., “Histological Examination on Achilles Tendon Lesions Induced by Quinolone Antibacterial Agents in Juvenile Rats,” Toxicologic Pathology, Vol. 23, No. 3, 1995, pp. 85-392. doi:10.1177/019262339502300315
[45]	R. J. Williams III, et al., “The Effect of Ciprofloxacin on Tendon, Paratenon, and Capsular Fibroblast Metabolism,” American Journal of Sports Medicine, Vol. 28, No. 3, 2000, pp. 364-369.
[46]	G. K. Kim, “The Risk of Fluoroquinolone-Induced Tendinopathy and Tendon Rupture: What Does the Clinician Need to Know?” Journal of Clinical and Aesthetic Dermatology, Vol. 3, No. 4, 2010, pp. 49-54.
[47]	P. Szaro, et al., “Fascicles of the Adult Human Achilles Tendon—An Anatomical Study,” Annals of Anatomy, Vol. 191, No. 6, 2009, pp. 586-593. doi:10.1016/j.aanat.2009.07.006
[48]	H. Vyas and G. Krish-naswamy, “Images in Clinical Medicine. Quinolone-Associated Rupture of the Achilles’ Tendon,” New England Journal of Medicine, Vol. 357, No. 20, 2007, p. 2067. doi:10.1056/NEJMicm061227
[49]	T. Movin, et al., “Pathology of the Achilles Tendon in Association with Ciprofloxacin Treatment,” Foot & Ankle International, Vol. 18, No. 5, 1997, pp. 297-299.
[50]	C. B. Landersdorfer, et al., “Penetration of Moxifloxacin into Bone Evaluated by Monte Carlo Simulation,” Antimicrobial Agents and Chemotherapy, Vol. 53, No. 5, 2009, pp. 2074-2081. doi:10.1128/AAC.01056-08